BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 10029573)

  • 21. Identification of B94 (TNFAIP2) as a potential retinoic acid target gene in acute promyelocytic leukemia.
    Rusiniak ME; Yu M; Ross DT; Tolhurst EC; Slack JL
    Cancer Res; 2000 Apr; 60(7):1824-9. PubMed ID: 10766166
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In acute promyelocytic leukemia NB4 cells, the synthetic retinoid CD437 induces contemporaneously apoptosis, a caspase-3-mediated degradation of PML/RARalpha protein and the PML retargeting on PML-nuclear bodies.
    Giannì M; de Thé H
    Leukemia; 1999 May; 13(5):739-49. PubMed ID: 10374879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia.
    Grignani F; De Matteis S; Nervi C; Tomassoni L; Gelmetti V; Cioce M; Fanelli M; Ruthardt M; Ferrara FF; Zamir I; Seiser C; Grignani F; Lazar MA; Minucci S; Pelicci PG
    Nature; 1998 Feb; 391(6669):815-8. PubMed ID: 9486655
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Response to histone deacetylase inhibition of novel PML/RARalpha mutants detected in retinoic acid-resistant APL cells.
    Côté S; Rosenauer A; Bianchini A; Seiter K; Vandewiele J; Nervi C; Miller WH
    Blood; 2002 Oct; 100(7):2586-96. PubMed ID: 12239173
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blockade of the ubiquitin protease UBP43 destabilizes transcription factor PML/RARα and inhibits the growth of acute promyelocytic leukemia.
    Guo Y; Dolinko AV; Chinyengetere F; Stanton B; Bomberger JM; Demidenko E; Zhou DC; Gallagher R; Ma T; Galimberti F; Liu X; Sekula D; Freemantle S; Dmitrovsky E
    Cancer Res; 2010 Dec; 70(23):9875-85. PubMed ID: 20935222
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient.
    Koken MH; Daniel MT; Gianni M; Zelent A; Licht J; Buzyn A; Minard P; Degos L; Varet B; de Thé H
    Oncogene; 1999 Jan; 18(4):1113-8. PubMed ID: 10023688
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trivalent antimonials induce degradation of the PML-RAR oncoprotein and reorganization of the promyelocytic leukemia nuclear bodies in acute promyelocytic leukemia NB4 cells.
    Müller S; Miller WH; Dejean A
    Blood; 1998 Dec; 92(11):4308-16. PubMed ID: 9834237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Granulocytic differentiation of human NB4 promyelocytic leukemia cells induced by all-trans retinoic acid metabolites.
    Idres N; Benoît G; Flexor MA; Lanotte M; Chabot GG
    Cancer Res; 2001 Jan; 61(2):700-5. PubMed ID: 11212271
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins.
    Rego EM; He LZ; Warrell RP; Wang ZG; Pandolfi PP
    Proc Natl Acad Sci U S A; 2000 Aug; 97(18):10173-8. PubMed ID: 10954752
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RXRα ligand Z-10 induces PML-RARα cleavage and APL cell apoptosis through disrupting PML-RARα/RXRα complex in a cAMP-independent manner.
    Xu L; Zeng Z; Zhang W; Ren G; Ling X; Huang F; Xie P; Su Y; Zhang XK; Zhou H
    Oncotarget; 2017 Feb; 8(7):12311-12322. PubMed ID: 28129653
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells.
    Giannì M; Koken MH; Chelbi-Alix MK; Benoit G; Lanotte M; Chen Z; de Thé H
    Blood; 1998 Jun; 91(11):4300-10. PubMed ID: 9596679
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting expression of the leukemogenic PML-RARα fusion protein by lentiviral vector-mediated small interfering RNA results in leukemic cell differentiation and apoptosis.
    Ward SV; Sternsdorf T; Woods NB
    Hum Gene Ther; 2011 Dec; 22(12):1593-8. PubMed ID: 21846246
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic targeting of nuclear receptor corepressor misfolding in acute promyelocytic leukemia cells with genistein.
    Ng AP; Nin DS; Fong JH; Venkataraman D; Chen CS; Khan M
    Mol Cancer Ther; 2007 Aug; 6(8):2240-8. PubMed ID: 17699721
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RAR alpha mutation.
    Shao W; Benedetti L; Lamph WW; Nervi C; Miller WH
    Blood; 1997 Jun; 89(12):4282-9. PubMed ID: 9192750
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Common defects of different retinoic acid resistant promyelocytic leukemia cells are persistent telomerase activity and nuclear body disorganization.
    Nason-Burchenal K; Maerz W; Albanell J; Allopenna J; Martin P; Moore MA; Dmitrovsky E
    Differentiation; 1997 Aug; 61(5):321-31. PubMed ID: 9342843
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia.
    Jing Y
    Leuk Lymphoma; 2004 Apr; 45(4):639-48. PubMed ID: 15160934
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia.
    Guidez F; Ivins S; Zhu J; Söderström M; Waxman S; Zelent A
    Blood; 1998 Apr; 91(8):2634-42. PubMed ID: 9531570
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Altered ligand binding and transcriptional regulation by mutations in the PML/RARalpha ligand-binding domain arising in retinoic acid-resistant patients with acute promyelocytic leukemia.
    Côté S; Zhou D; Bianchini A; Nervi C; Gallagher RE; Miller WH
    Blood; 2000 Nov; 96(9):3200-8. PubMed ID: 11050004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Frequent mutations in the ligand-binding domain of PML-RARalpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo.
    Zhou DC; Kim SH; Ding W; Schultz C; Warrell RP; Gallagher RE
    Blood; 2002 Feb; 99(4):1356-63. PubMed ID: 11830487
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway.
    Yoshida H; Kitamura K; Tanaka K; Omura S; Miyazaki T; Hachiya T; Ohno R; Naoe T
    Cancer Res; 1996 Jul; 56(13):2945-8. PubMed ID: 8674046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.